Vanda Pharmaceuticals (VNDA) Tops Q4 Views
Vanda Pharmaceuticals (NASDAQ: VNDA) reported Q4 EPS of $0.36, $0.35 better than the analyst estimate of $0.01. Revenue for the quarter came in at $53.04 million versus the consensus estimate of $51.7 million.
GUIDANCE:
2019 Financial Guidance
Vanda expects to achieve the following financial objectives in 2019:
Full Year 2019 Guidance | |
Combined net product sales from both HETLIOZ® and Fanapt® | $215 to $225 million |
HETLIOZ® net product sales | $137 to $143 million |
Fanapt® net product sales | $78 to $82 million |
Year-end 2019 Cash | Greater than $260 million |
For earnings history and earnings-related data on Vanda Pharmaceuticals (VNDA) click here.